Xanodyne Pharmaceuticals Appoints New Chief Operating Officer

Tuesday, May 17, 2011 General News
Email Print This Page Comment bookmark
Font : A-A+

NEWPORT, Ky. and MOUNT ARLINGTON, N.J., May 17, 2011 /PRNewswire/ -- Xanodyne Pharmaceuticals,

Inc., is pleased to announce that Fabrice Egros has been appointed to the position of Chief Operating Officer reporting to Natasha Giordano, President and Chief Executive Officer.

Fabrice Egros has more than 20 years of experience in the pharmaceutical industry and prior to Xanodyne served in various senior positions in UCB Pharmaceuticals (Belgium, US and Japan). His depth of experience includes senior leadership positions in general management, corporate business development, clinical development & regulatory as well as marketing and sales in Europe, Asia and the US at major pharmaceutical companies including Sanofi-Aventis and Parke-Davis.

Mr. Egros said, "I look forward to working with Natasha and the management team in continuing to drive toward our vision of being a leader in the pain management category. Xanodyne has a proven track record of bringing innovative products to the market and developing strategic partnerships where desired, as well as the people, resources and strategy to focus Xanodyne on high growth opportunities within the pain franchise."

Ms. Giordano said, "I am very pleased to welcome Fabrice to our management team. His global knowledge of the industry, deep experience in corporate development and his strong leadership will help us achieve our strategic goals and commercial success in pain management."

About Xanodyne Pharmaceuticals, Inc.

Xanodyne Pharmaceuticals, Inc., founded in 2001, is an integrated specialty pharmaceutical company with both development and commercial capabilities focused on pain management. Xanodyne markets a portfolio of prescription pharmaceuticals and a line of prenatal vitamins. Additionally, we are advancing a late stage pipeline of product candidates targeted at significant potential markets in Xanodyne's focus area. For more information, visit www.Xanodyne.com.

SOURCE Xanodyne Pharmaceuticals, Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Find a Doctor
Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook